In vitro pharmacology of Ambroxol (cas 18683-91-5): Potential serotonergic sites of action
-
Add time:09/25/2019 Source:sciencedirect.com
AimsAmbroxol is a muco-active agent with multiple, clinically relevant effects in the airway. Despite its widespread use and well documented clinical efficacy, there are few data on its mechanism of action and receptor pharmacology beyond sodium channel blockade and inhibition of guanylate cyclase. Accordingly, in vitro studies were conducted to determine its overall receptor pharmacology and possible sites of action.
We also recommend Trading Suppliers and Manufacturers of Ambroxol (cas 18683-91-5). Pls Click Website Link as below: cas 18683-91-5 suppliers
Prev:Short CommunicationEffect of Ambroxol (cas 18683-91-5) chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease
Next:Time-shifted co-administration of sub-analgesic doses of Ambroxol (cas 18683-91-5) and pregabalin attenuates oxaliplatin-induced cold allodynia in mice) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Ambroxol (cas 18683-91-5) as a pharmacological chaperone for mutant glucocerebrosidase09/30/2019
- Original articleThe chaperone activity and toxicity of Ambroxol (cas 18683-91-5) on Gaucher cells and normal mice09/29/2019
- Original ArticleCiprofloxacin plus erythromycin or Ambroxol (cas 18683-91-5) ameliorates endotracheal tube-associated Pseudomonas aeruginosa biofilms in a rat model09/28/2019
- Inhalation of Ambroxol (cas 18683-91-5) inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway10/01/2019
- Chapter Eight - A comparative computational approach toward pharmacological chaperones (NN-DNJ and Ambroxol (cas 18683-91-5)) on N370S and L444P mutations causing Gaucher's disease09/27/2019
- Time-shifted co-administration of sub-analgesic doses of Ambroxol (cas 18683-91-5) and pregabalin attenuates oxaliplatin-induced cold allodynia in mice09/26/2019
- Short CommunicationEffect of Ambroxol (cas 18683-91-5) chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease09/24/2019
- Protective effects of Ambroxol (cas 18683-91-5) in psoriasis like skin inflammation: Exploration of possible mechanisms09/10/2019
